



Mindray Medical International Limited Acquisition of Datascope PMB Business

March 2008



Disclaimer

This material contains forward-looking statements with respect to the Company's plans to complete the acquisition transaction, expectation of obtaining acquisition financing and government approvals, anticipated synergies from the acquisition, the timing of and degree to which the acquisition is accretive, the Company's ability to build a competitive presence in the United States and Europe, the Company's ability to tailor products to satisfy consumer demands and enhance product functionality, the Company's expectation to maintain existing product lines and personnel, the outlook regarding market share in specific product markets and geographies, outlook regarding drivers, developments and trends affecting its worldwide markets, new product development and commercial launch dates. These statements are based on information available at the time they are made and are subject to a number of risks and uncertainties. Actual results could differ materially from those anticipated by these forward-looking statements as a result of a number of factors, some of which may be beyond the company's control. Factors that affect the Company's business operations and product development, as well as a further list and description of risks and uncertainties associated with Mindray's business, are discussed in its reports filed with the Securities and Exchange Commission, including its most recent annual report on Form 20-F. Mindray disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Transaction Overview

Mindray is pleased to announce the execution of a definitive agreement with Datascope to acquire its Patient Monitoring business, to be integrated into the global strategy of Mindray

| | |
|----------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Assets Included: | Patient Monitoring business (“PMB”) Mahwah manufacturing facility Trademarks Global Technology Services business associated with Patient Monitoring business Direct sales force Intellectual property Netherlands warehouse facility |
| Purchase Consideration^{1,2}: | \$240 million (implied CY 07 revenue multiple of 1.5x) |
| Timing: | Deal expected to close in Q2 2008, subject to customary closing conditions and regulatory approvals |
| Financing: | Will be financed by cash on balance sheet and debt |
| Non-GAAP EPS Impact: | Expected to be accretive in 09 |

Note:

1 Based on reported CY07 revenue for patient monitoring business of \$161.3mm

2 \$202 million in cash and \$38m in account receivables to be retained by Datascope

Transaction Highlights


| | |
|------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Global Footprint | <ul style="list-style-type: none">■ Broadens Mindray international presence and significantly increases US operational footprint■ Increases MR total 07 revenue base by ~53% |
| US Infrastructure & Direct Distribution | <ul style="list-style-type: none">■ Provides immediate direct sales and service capabilities in US■ Enhances R&D capabilities for the combined entity■ Creates cross-selling opportunities for MR's product lines |
| Strong Brand | <ul style="list-style-type: none">■ The Mindray/PMB combination will bring together two leading brands in patient monitoring■ Use of the Datascope brand through 2015 |
| Manufacturing and R&D Outsourcing Savings | <ul style="list-style-type: none">■ Significant opportunity to improve gross margins on DSCP stand-alone monitors■ Enhanced product offerings with access to China-based R&D capabilities |
| Significant Operating Synergies | <ul style="list-style-type: none">■ Mindray expects to achieve approximately \$30mm of run-rate synergies in the areas of manufacturing, SG&A and R&D within 3 years |

Datascope Patient Monitoring Business




- Division of Datascope, a publicly traded company on NASDAQ (DSCP)
- Headquartered in Mahwah, NJ
- ~440 employees worldwide
- Provides broad array of patient monitoring products
- Three major product lines
 - Standalone Monitors
 - Central Monitoring Systems
 - Anesthesia Delivery Systems
- CY07 revenue of \$161.3mm

Transaction Creates A Global Player...



... Creating the #3 Global Leader in Patient Monitoring



Source: 2007 Frost & Sullivan research

A Perfect Fit of Complementary Assets...




- Leading market position in China
- Established and rapidly growing presence outside of China
 - Sales in more than 140 countries
 - More than 1,200 international distributors
- Revenue growth of 47% and net income growth of 64% in 2007
- World-class R&D platform with more than 1,000 R&D engineers
- More than 3,700 employees worldwide



- Strong brand name in US patient monitoring market
- Leading share in specific sub-segments of US Patient Monitoring Market¹:
 - > 50% share in Ambulatory Surgery Centers
 - 10-15% in Hospital Anesthesia Market
 - ~ 20% in Vital Signs Monitoring
- Large, established US and European direct sales and service organization dedicated to patient monitoring
- Recent approval of innovative, wireless monitoring solution, NetGuard

... More than the Sum of its Parts


Datascope PMB's
direct sales and
service team
in US & Europe



Cross-selling opportunities,
better distribution for
Mindray's high price-to-
performance products



Mindray's efficient
component sourcing
and China-based R&D




Enhanced ability to tailor /
add functionality to
Datascope products, better
and faster response to
customer needs

Pro Forma Operating Strategy

- Mindray's new US subsidiary, that will contain the Datascope PMB business, will be run by David Gibson, current President of Datascope PMB
- Mindray intends to keep substantially all of Datascope PMB employees in all areas, including sales & marketing, service, R&D and manufacturing
- Operating synergies will be achieved from manufacturing, SG&A and R&D








Clear Roadmap for Successful Integration



Value Contribution

Datascope's Leading Product Portfolio



| Customer Segment | Product | Product Segment | |
|------------------|-----------------------|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Emergency Room | 1 Spectrum | Standalone Monitors |  1  2  3 |
| | 2 Passport 2 | | |
| | 3 Trio | | |
| Vital Signals | 4 Accutorr Plus | |  4  5 |
| | 5 Duo | | |
| Operating Room | 6 Spectrum OR Monitor | |  6  7 |
| | 7 Gas Module SE | | |
| | 8 Anestar S/Plus | | |
| 9 AS-3000 | | | |
| 10 Artema | | | |
| Telemetry | 11 Panorama | | Central Monitoring System |

Value Contribution

Established Sales & Service Network

US

- **Direct Sales Model**
 - 86 sales and clinical support personnel in US
 - Dedicated national account representatives
 - Sales representatives
 - Regional managers
 - Clinical support specialists
- **Direct Service**
 - Direct field service
 - Employees have been with Datascope for 15 years on average

International

- **Direct Sales Model with 17 sales reps and 4 clinical support specialists**
 - France
 - Germany
 - UK
- **Distributor Model**
 - Brazil
 - HK
 - Caribbean
 - Mexico
 - Chile
 - Columbia
- **Direct Service**
 - UK
 - Germany
 - France
 - Benelux
 - Egypt
 - HK

2007 Pro-Forma Operating Metrics

| | Mindray | Datascope PMB | Mindray + Datascope PMB |
|----------------------------------|---------|---------------|----------------------------|
| Global Market Share ¹ | 4% | 5% | 9% |
| # Employees | 3,705 | 442 | 4,147 |
| R&D Staff | 1,036 | 81 | 1,117 |
| # FDA Approved Products | 13 | 20 | 33 |
| Revenue (\$mm) | 305.8 | 161.3 | 467.1 |

Note:

1 2007 Frost & Sullivan research



Thank you!

Q&A